Monalizumab - Innate Pharma
Alternative Names: Anti-NKG2A; IPH-22; IPH-2201; IPH-22XX; NN-8765; NNC 0141-0000-0100Latest Information Update: 29 Dec 2024
At a glance
- Originator Novo Nordisk
- Developer AstraZeneca; Innate Pharma; Istituto Clinico Humanitas; NCIC Clinical Trials Group; Netherlands Cancer Institute; Novo Nordisk
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; NK cell lectin-like receptor subfamily C antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Acute myeloid leukaemia; Bladder cancer; HER2 positive breast cancer; Myelodysplastic syndromes; Small cell lung cancer; Squamous cell cancer
- Phase I/II Cervical cancer; Chronic lymphocytic leukaemia; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- No development reported Haematological malignancies
- Discontinued Inflammation; Rheumatoid arthritis
Most Recent Events
- 12 Dec 2024 Phase-II clinical trials in Bladder cancer (Combination therapy) in USA (IV) (NCT06503614)
- 09 Sep 2024 Efficacy and adverse event data from the phase II NeoCOAST 2 trial released by Innate Pharma
- 31 May 2024 Adverse events and efficacy data from a phase II COAST trial in Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)